Efficacy and Safety of Middle Meningeal Artery Embolization for Patients with Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis

Kabir N<sup>1</sup>, Owais B<sup>1</sup>, Trifan G<sup>1</sup>, Testai FD<sup>1</sup>

<sup>1</sup> Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, Chicago, Il

Corresponding author: Kabir, Nabihah, MD Department of Neurology and Rehabilitation University of Illinois College of Medicine at Chicago Chicago, II, 60612 Email: nabihah@uic.edu

Keywords: chronic subdural hemorrhage, middle meningeal artery embolization, recurrent hematoma, best medical management

1 **Background:** Chronic subdural hematoma (CSDH) is characterized by the collection of blood 2 beneath the dura mater. Traditional treatments involve surgical drainage of the hematoma, but 3 recurrence rates can be high. A highly vascularized neo-membrane irrigated by the middle 4 meningeal artery (MMA) may be involved in CSDH re-accumulation. 5 **Objective:** We conducted a systematic review and meta-analysis of studies that compared the 6 efficacy and safety of MMA embolization to conventional treatment alone for CSDH. 7 Material and Methods: A systematic search of PubMed, Embase Ovid, and ClinicalTrials.gov 8 identified observational and randomized clinical studies comparing MMA embolization to 9 conventional treatment for chronic subdural hematoma. The efficacy outcomes were hematoma 10 recurrence and good functional outcome (as defined by a modified Rankin Scale score (mRS) of 11 0-2). Safety outcomes were the rate of major complication and mortality. Heterogeneity among 12 studies were evaluated using the  $l^2$  statistic. Analyses were conducted using Cochrane Review 13 Manager software, with risk ratios (RR) and 95% confidence intervals (95% CI) presented for 14 key outcomes. Absolute risk reduction (ARR, 95% CI) 1000 patients were also calculated using 15 GRADEpro software. 16 Results: The analysis included data from 13 studies (4 RCTs and 9 observational studies) with 17 a total number of 2960 patients (35.3% in the MMA group and 64.7% in the conventional 18 treatment group). Compared to conventional treatment, MMA embolization decreased risk of 19 hematoma recurrence by 60% (13 studies, RR=0.40, 95% CI 0.25-0.63;  $I^2$ =50%), for an 20 absolute effect of 119 fewer events/1000 patients (95% CI 70-149), with similar risk of major 21 complications (9 studies, RR=0.82, 95% CI=0.54-1.25) and mortality risk (13 studies, RR=0.90, 22 95% CI=0.54-1.51). In subgroup analyses by study type, pooled results from RCTs showed 23 similar direction effects as those from observational studies for both efficacy and safety 24 outcomes. 25 **Conclusion:** MMA embolization in CSDH management is a safe and effective approach for

26 CSDH.

## 27 Introduction

28

29 Chronic subdural hematoma (CSDH) refers to the accumulation of blood, blood-degradation 30 products, of fluid between the dura mater and the arachnoid. CSDH affects preponderantly the 31 elderly and has an estimated incidence of 1.7 to 20.6 per 100,000 persons per year.<sup>1</sup> However, 32 based on the increase in global life expectancy and the trends obtained in observational studies. it is projected that the incidence of this condition will continue to rise<sup>2</sup>. The traditional 33 34 management of CSDH, which includes surgical drainage, is associated with periprocedural 35 complications and recurrence rates that range from 3% to 30%<sup>3</sup>. Historically, it was considered 36 that CSDH was the consequence of venous oozing secondary to traumatic injury of the bridging 37 veins. However, cumulative evidence indicates that, although trauma, even if mild, may 38 constitute an initial insult, the pathogenesis of CSDH involves the development of a layer of 39 connective tissue cells that leads to the formation of a new membrane<sup>4</sup>. This membrane is 40 enriched in pro-inflammatory and pro-angiogenic mediators, such as tissue-plasminogen 41 activators, matrix-metalloproteinases, and vascular endothelial growth factor. These mediators 42 contribute to the development of leaky vessels that result in repeated microbleeds and the 43 exudation of fluid. This phenomenon further enhances inflammation and results in a vicious 44 cycle that perpetuates CSDH and contributes to its recurrence. 45 Since the vascular supply to this new membrane derives from the middle meningeal artery 46 (MMA), it has been proposed that the embolization of the MMA may reduce the risk of 47 hematoma growth and recurrence. Since the MMA is a branch of the external carotid artery, it 48 was considered that this procedure would not significantly increase the risk of cerebrovascular 49 complications. Data supporting the benefit and safety of endovascular embolization of the MMA 50 as an adjunct to surgical drainage originates from non-randomized retrospective studies and 51 registries. In a meta-analysis including non-randomized studies, MMA embolization had lower 52 rates of CSDH recurrence and need for surgical rescue with comparable rates of in-hospital

- 53 complications<sup>5</sup>. The results of three randomized clinical trials (RCTs) assessing the benefits and
- risks of MMA embolization as an adjunct therapy for patients with CSDH were recently

reported<sup>6789–11</sup>. Here we present the results of a meta-analysis where we assessed the efficacy

- and safety of MMA for the treatment of patients with CSDH.
- 57

### 58 Material and Methods

- 59 Our study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- 60 (PRISMA) statement guidelines<sup>12</sup>. This protocol is registered in PROSPERO, trial number
- 61 IDCRD42024515860. Data is available from the corresponding author upon reasonable request.
- 62 No informed consent was required from the human subjects given the nature of the analysis.
- 63

### 64 Eligibility Criteria and Outcomes

This study included randomized controlled clinical trials and observational studies that

66 compared the efficacy and safety of MMA embolization plus standard of care (conservative or

67 surgical treatment) to standard of care alone for patients with CSDH. Studies that only reported

outcomes for MMA embolization without separately reporting the outcomes for conventional

69 management only, case reports, and non-peer-reviewed studies were excluded. The primary

- 70 efficacy outcome was the risk of hematoma recurrence, and the safety outcome was mortality
- risk. In a secondary analysis, we investigated the risk of good functional outcomes defined as

72 modified Rankin Scale Score (mRS) of 0-2 at follow-up and the frequency of major

complications. **Supplemental Table 1** depicts the definitions used in each trial. Given the wildly

- variable definitions for the safety endpoints used in the RCTs (Supplementary Table 2), we
- only report here the rates of safety points from each RCT, while presenting the pooled results of

76 safety outcomes of the observational studies.

### 77 Information Sources and Search Methods

We queried PubMed, Embase Ovid, and ClinicalTrials.gov from inception to February 2024. The search algorithm is shown in **Appendix 1**. The results were screened for inclusion criteria by 2 of the authors (GT and FDT). Disagreements were resolved using the other two authors (NK and BO). Information on trial design, sample size, mean age, sex, laterality of the hematoma (unilateral vs bilateral), etiology, baseline CSDH volume or thickness, and mean follow-up time, along with the safety and efficacy outcomes were collected.

### 84 Statistical Analyses and Bias Assessment

Two of the authors (GT and FDT) independently determined the risk of bias in RCTs using the 85 RoB2 (Revised Cochrane Risk of Bias) tool<sup>13</sup>; the risk of bias in nonrandomized studies was 86 assessed using the intervention (ROBINS-I) tool<sup>14</sup>. Publication bias was investigated by visual 87 88 inspection of funnel plots for asymmetry for each reported outcome. Heterogeneity between 89 studies was quantified using  $l^2$  statistic, and as recommended by the American Heart 90 Association<sup>15</sup>, using the following cut-offs: 0–40%: might not be important; 30–60%: may 91 represent moderate heterogeneity; 50-90%: may represent substantial heterogeneity; and 75-92 100%: considerable heterogeneity. To further investigate heterogeneity, subgroup analysis by 93 study design was performed. Analyses were done using Cochrane Review Manager (v 5.4)<sup>16</sup>. Descriptive characteristics of 94 95 the included studies were recorded. Event rates for each efficacy and safety outcome of interest 96 were compared between MMA embolization plus conventional treatment and conventional 97 management alone. Results are presented as risk ratios along with their corresponding 95% 98 confidence intervals (CI), using random-effects Mantel-Haenszel method. The absolute number 99 of events per 1000 patients (absolute risk reduction, 95% CI) was calculated using the

101

100

GRADEpro software<sup>17</sup>.

102

103

### 104 Results

### 105 Study Selection and Characteristics

106 The search yielded a total of 3.978 records. Of these, 13 studies with 2.960 patients (35.3% in 107 the MMA group and 64.7% in the conventional treatment group) were included in the final 108 analysis (Figure 1). There were 9 observational studies and 4 RCTs. Three of the RCTs were recently presented at the 2024 International Stroke Conference<sup>6789–11</sup>. Baseline characteristics 109 110 of the included studies are presented in Table 1. In the MMA group, mean (SD) age was 72.4± 111 4.6 years, 73.3% were males, and mean SDH thickness was 18± 4.6. Comparatively, in the 112 MMA group mean age was 70.6± 5.4 years, 70% were males, and the mean SDH thickness 113 was 18.5± 4.7 mm. Mean follow-up time between groups was similar among groups (3.2 114 months). The risk of bias across all studies, and for each included study is shown in 115 Supplementary Figure 1. Visual inspection of the funnel plots revealed symmetry for the main

116 outcomes (Supplementary Figure 2).

### 117 Efficacy outcomes

118 **Figure 2** depicts the risk of hematoma recurrence between adjunct MMA embolization and

119 conventional management alone for all studies. There was an absolute effect of 119 fewer

events per 1,000 patients (95% CI 70-149) and an overall risk reduction of 60% in favor of

adjunct MMA embolization compared with conventional treatment alone (13 studies, RR=0.40,

122 95% CI 0.25-0.63) with moderate heterogeneity ( $I^2$ =50%). When analyzing by study design,

123 data from RCTs showed a risk reduction of hematoma recurrence with adjunct MMA

embolization of 52% (4 studies, RR=0.48, 95% CI=0.34-0.67), with low heterogeneity (I<sup>2</sup>=15%)

- and an absolute effect of 86 fewer hematoma recurrences per 1,000 participants (95% CI 54-
- 126 109) (Figure 2). In comparison, observational studies showed a 74% risk reduction for
- hematoma recurrence in favor of adjunct MMA (RR=0.26, 95% CI= 0.10-0.66) with substantial

- heterogeneity ( $I^2$ =64%) and an absolute effect of 167 fewer recurrences per 1,000 participants
- 129 (95% CI 63-203) (**Figure 2**).
- 130 Rates for good functional outcomes were available for 4 studies only (1 RCT and 3
- 131 observational studies). Overall risk for good functional outcome was similar between groups
- 132 (RR=1.02, 95% CI=0.98 -1.06) with no heterogeneity (I<sup>2</sup>=0%) (**Figure 2**).
- 133 Safety outcomes
- 134 **Figure 3** depicts the risk of major complications and mortality rates. Overall, the pooled risk of
- 135 major complications for all observational studies was 29% lower in the MMA group compared
- 136 with conventional treatment alone (9 studies, RR=0.82, 95% CI 0.54-1.25) with no heterogeneity
- 137 (l<sup>2</sup>=0%). The safety endpoint rates reported in each RCT varied between 5% to 16% for the
- 138 MMA group, compared to 4% to 22% in the conventional treatment group. Mortality rates were
- similar as well for both groups (13 studies, RR=0.90, 95% CI=0.54 -1.51) with no heterogeneity
- $(l^2=0\%)$ . When analyzed by study design, mortality rates were comparable for RCTs (RR=0.82,
- 141 95% CI 0.28-2.34; I<sup>2</sup>=45%) and observational studies (RR=0.87, 95% CI=0.42-1.81, I<sup>2</sup>=0%)
- 142 (**Figure 3**).

143

# 144 Discussion

145 The results of our meta-analysis show that MMA embolization added to conventional treatment 146 is superior to conventional treatment alone for the treatment of CSDH. Previous meta-analyses 147 that included data from retrospective cohorts have shown that MMA embolization is associated with lower rates of hematoma recurrence and fewer complications<sup>15</sup>. However, the lack of data 148 149 from RCTs confounded the interpretation of these results. Limitations like retrospective data and 150 lack of separate reporting for conventional treatment hampered their generalizability<sup>5</sup>. This 151 updated meta-analysis addresses these issues by including recent RCTs and observational 152 studies with direct comparisons between MMA embolization with adjunct standard care and standard care alone. In our study, which included the results from three new RCTs<sup>678</sup>, we 153

154 observed a 60% reduction in overall hematoma recurrence risk in favor of MMA embolization 155 plus conventional treatment compared to conventional treatment alone, for an absolute risk 156 reduction of 86 fewer hematoma recurrences per 1000 participants. In the subgroup analysis by 157 study design, the rate of hematoma recurrence reduction in favor of MMA was higher in 158 observational studies than in RCTs (74% vs. 52%). These differences could be explained, at 159 least in part, by methodologic factors, including patient selection, publication bias, and study 160 design. Also, several studies reported outcomes obtained in small cohorts which can increase 161 the type II error. Furthermore, the wide confidence intervals and moderate heterogeneity 162 observed in observational studies suggest elevated variability in the reported outcomes and 163 raise concerns about the precision of the calculated point estimates. In comparison, the analysis 164 using data from RCTs produced estimates with narrower confidence intervals and low 165 heterogeneity. Thus, the inclusion of adequately powered RCTs allows for a more accurate 166 estimation of the effect of MMA embolization on CSDH outcomes. This finding strengthens the 167 evidence for the efficacy of MMA embolization in chronic subdural hematoma. 168

169 The surgical interventions used for the treatment of CSDH, like burr-hole evacuation, are 170 considered safe. However, the rate of perioperative complications and mortality observed in 171 CSDH cohorts varies from 0% to 32%. These complications are not always caused by the 172 surgical procedure itself but are secondary to other factors such as preexisting active medical 173 conditions and frailty<sup>18,19</sup>. MMA embolization, which is typically done endovascularly, is well 174 tolerated and is also considered safe. The MMA contributes minimally to cerebral blood flow, 175 and collateral circulation can effectively compensate for the blocked MMA, minimizing the risk of 176 cerebrovascular complications. Additionally, embolization is performed via the external carotid artery, further reducing the risk of ischemic stroke<sup>20</sup>. The overall incidence of complications in 177 cohorts treated with MMA embolization is less than 4%<sup>21</sup>. The safety of MMA embolization is 178 179 also supported by the results of previous meta-analyses which reported similar complication

rates for adjunct MMA embolization and conventional treatment groups.<sup>5 22</sup> In our study, there 180 181 were no significant differences in the safety endpoint or mortality for the pooled results, 182 indicating that MMA embolization plus conventional treatment provides a safe alternative to 183 conventional management alone for CSDH. Future studies should assess the long-term 184 durability of the MMA effect and whether this approach allows the use of anticoagulation in 185 patients who require such treatment. Similar to previous studies, we observed that MMA 186 embolization as an adjunct treatment does not improve functional outcomes compared to 187 conventional management alone<sup>22</sup>. However, it should be noted that most of the studies 188 included in this analysis ascertained functional outcomes using the mRS. This scale is widely 189 used in stroke research. However, the sensitivity of this tool to detect differences in disability in 190 the particular case of SDH, where the neurologic deficits may be subtle, has not been well 191 described.

192

### 193 Limitations

194 Our meta-analysis has several limitations. First, the conventional treatment was not 195 standardized among studies; thus, there are intrinsic variations among the studies that we are 196 not able to account for. Second, there is variability in the definitions of efficacy and safety 197 outcomes among studies. Third, the majority of the studies included in our analysis had an observational retrospective design with the consequent risk of selection bias<sup>23</sup>. In addition, many 198 199 of them were performed in small cohorts and did not include power calculations. However, in 200 subgroup analysis, we observed that the results reported in observational studies are 201 comparable to those obtained in adequately powered RCTs. Fourth, we reported our results as 202 RRs and absolute effects. Because the absolute risk for control varies between trials, these 203 estimates should be interpreted with caution. However, our meta-analysis is the largest study 204 comparing the efficacy and safety of MMA as adjunct therapy to standard treatment alone for 205 patients with CSDH. In addition, we included the results of three large RCTs which, combined,

- accounted for almost 75% of the final sample size and allowed us to calculate point estimates
- with low heterogeneity.
- 208
- 209

# 210 Conclusion


- 211 MMA embolization as an adjunct treatment significantly decreases the recurrence of CSDH
- 212 without increasing the risk of morbidity or mortality when compared to conventional treatment
- alone. Several studies are currently underway to compare the efficacy and safety of MMA
- embolization as a standalone treatment for CSDH.

# Table 1. Baseline Characteristics 5

				Lost to	follow	Mean mm	+SD or			Traumatic	פחש	Bilateral	SUH	Median (IQR)vol/t s of basel		Mean follo	
Study, year	Design	Sample size		Lost to follow up/Exited, n(%)		median (IQR) age		Male, N(%)		n(%)		n(%)		SDH in mm		time (months)	
	<b>.</b>	MMA Treatme	MA	MMA		MMA	Conve	MMA		мма		ММА	Conve	MMA Treatme	Conve	MMA Treatme	Conve
		nt	ntional	treatment	Conven tional	nt	ntional	Treatmen t	Conve ntional	Treatment	Conve ntional	Treatment		nt	ntional	nt	ntional
	1		intionial	ucutiliciti	lional	72.98±11.	70.99±1	•	maomai	meatment	Intionial	meatment	maomai		maonar		maomai
						01 or	1.28 or		73.40				18.20		21.4±6.		
EMBOLISE, 2024	RCT	197	203	30 (15)	23 (11)	[74.7]	[ 72.5]	72.60%		NR	NR	21.30%		21.6±6.3	2	3	3
,				. ,	· · · ·									22.8	22.4(1		
						68.5 (60-	70 (61-				201			(18.6-	8.5-		
MAGIC-MT, 2024	RCT	360	362	NR	NR	74)	75)	81.10%	84%	178 (49.4)	(55.5)	NR	NR	27.1)	26.8)	3	3
							74.2±10										
STEM, 2024	RCT	149	161	NR	NR	74.2 ± 9.8	.3	67.2	74.5	NR	NR	NR	NR	NR	NR	3	3
Onyinzo et al,					31		77.4±10		53						23.5±4.		
2021	OR	50	82	28 (56%)	(37%)	79.2	.3	42 (84%)	(65%)	NR	NR	NR	NR	21	7	3	3
															18.1		
Marulanda et al,						75 (70-	82(67-							19(14-	(10.9-		
2021	OR	25	25	0	0	87)	88)	14 (56)	16 (64)	10 (40)	7 (28)	0 (0)	0(0)	23.4)	26.1)	2	3
Catapano et al,									139		144		86				
2021	OR	35	196	NR	NR	68±12	71±13	25 (71%)	(71%)	23 (66%)	(73%)	6 (17%)	(43%)	15±3.9	15.3	3-4	3-4
Carpenter et al,							70.2±12		123				46				
2021	OR	23	185	1 (4%)	5 (2%)	61±6.2	.6	18 (82%)	(67%)	NR	NR	4 (17%)	(25%)	18±6	18±5	3-4	3-4
									123				36				
Shotar et al, 2020	OR	89	174	6 (6%)	12 (6%)	74±13	77±12	68 (76%)	(71%)	NR	NR	15 (17%)	(21%)	NR	NR	3	3
					a (a)		74.7±13										
Ng et al, 2019	RCT	21	25	1 (5)	2 (8)	77.4±10.9		10 (53)	13 (59)	12 (63)	15 (68)	3 (16)	3 (14)	6.4±5.7	6.8±5.3	3	3
				_		69.3±10.4		40.070()	347	45 (000)	272	40 (000)	107	40.0.5.00	20.3±6.		
Ban et al, 2018	OP	72	469	0	0	7	.16	48 (67%)	(74%)	45 (62%)	(58%)	19 (26%)	(23%)	19.6±5.00	47	3-6	3-6
Matsumoto et al,	0.0			_												_	
2018	OR	4	10	0	0	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	3	3
Kim at al. 0047		00		_		73.65±7.1		14 (70.0)	16(69.		47			40.017.50	21.01±		
Kim et al, 2017	OR	20	23	0	0	4	.91	14 (70.0)	6)	8	17	6	1	18.9±7.58	6.21	3	3
Lam et al, 2023	RCT	16	19	0	3	64.2	72.4	12	11	13	16	9	4	21.1	20.9	3	3

RCT-randomized control trial; OR-observational retrospective study; OP-observational prospective trial; NR=not reported

### Figure 1. PRISMA Flow Diagram




### MMA embolization **Conventional Management Risk Ratio Risk Ratio** Α Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% Cl RCTs EMBOLISE, 2024 0.36 (0.16. 0.78) 8 197 23 203 13.1% MAGIC-MT, 2024 24 360 36 362 17.1% 0.67 [0.41, 1.10] Ng et al, 2019 19 1 22 2.5% 1.16 [0.08, 17.28] STEM, 2024 Subtotal (95% CI) 0.39 [0.26, 0.60] 0.48 [0.34, 0.67] 23 149 63 161 18.0% 725 748 50.8% Total events 56 123 Heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 3.52, df = 3 (P = 0.32); l<sup>2</sup> = 15% Test for overall effect: Z = 4.27 (P < 0.0001) Not RTCs Ban et al, 2018 469 0.05 [0.01, 0.36] 72 129 4.4% Carpenter et al, 2021 23 21 185 10.8% 1.53 [0.58, 4.07] 0.09 [0.01, 0.63] 0.14 [0.02, 1.05] Catapano et al. 2021 35 62 196 4.4% 4.2% Kim et al, 2017 20 23 8 Lam et al, 2023 16 19 2.2% 0.17 [0.01, 3.03] 3 Marulanda et al, 2021 25 5 25 3.9% 0.20 [0.03, 1.59] Matsumoto et al, 2018 4 2 10 2.3% 0.44 [0.03, 7.58] 0 Onyinzo et al, 2021 50 11 82 4.1% 0.15 [0.02, 1.12] Shotar et al. 2020 89 24 174 12.9% 0.57 [0.26, 1.27] Subtotal (95% CI) 334 1183 49.2% 0.26 [0.10, 0.66] Total events 16 265 Heterogeneity: Tau<sup>2</sup> = 1.16; Chi<sup>2</sup> = 22.10, df = 8 (P = 0.005); l<sup>2</sup> = 64% Test for overall effect: Z = 2.81 (P = 0.005) Total (95% CI) 1931 100.0% 0.40 [0.25, 0.63] 1059 Total events 72 388 Heterogeneity: Tau<sup>2</sup> = 0.25; Chi<sup>2</sup> = 23.77, df = 12 (P = 0.02); l<sup>2</sup> = 50% 0.01 0.1 10 100 Test for overall effect: Z = 3.91 (P < 0.0001) Favours MMA embolization Favours Conventional Management Test for subgroup differences: Chi<sup>2</sup> = 1.43, df = 1 (P = 0.23), l<sup>2</sup> = 30.3%

# Figure 2. Efficacy outcome with and without MMA embolization.

	MMA emboli	zation	<b>Conventional Manage</b>	ement		Risk Ratio		Risk Ratio	<b>_</b>
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI	В
RCTs									
MAGIC-MT, 2024 Subtotal (95% CI)	335	360 360	333	362 362	88.5% 88.5%	1.01 [0.97, 1.05] 1.01 [0.97, 1.05]		<b>—</b>	
Total events	335		333						
Heterogeneity: Not a	pplicable								
Test for overall effect	: Z = 0.54 (P = 0	0.59)							
Not RCTs									
Lam et al, 2023	6	16	6	19	0.2%	1.19 [0.48, 2.97]			
Kim et al, 2017	17	20	20	23	2.6%	0.98 [0.77, 1.25]		-	
Onyinzo et al, 2021 Subtotal (95% CI)	29	31 67	69	82 124	8.8% 11.5%	1.11 [0.97, 1.27] 1.08 [0.96, 1.21]		•	
Total events	52		95						
Heterogeneity: Tau <sup>2</sup> : Test for overall effect			2 (P = 0.65); I <sup>2</sup> = 0%						
Total (95% CI)		427		486	100.0%	1.02 [0.98, 1.06]		•	
Total events	387		428						
Heterogeneity: Tau <sup>2</sup> :	= 0.00; Chi <sup>2</sup> = 2	.03, df = 3	3 (P = 0.57); I <sup>2</sup> = 0%				0.01	01 1	+ 10 10
Test for overall effect	: Z = 0.96 (P = 0	0.33)					0.01	Favours MMA embolization Favours Convention	
Test for subgroup dit	fferences: Chi <sup>z</sup> :	= 1.14, dt	(= 1 (P = 0.29), I <sup>2</sup> = 12.4	1%				arous min terrisonadion Tavous convention	onal management

Risk ratio for hematoma recurrence (A), and good functional outcome (mRS  $\leq$ 2) (B) for patients receiving adjunct MMA embolization to conventional management vs conventional management only. M-H indicates the Mantel-Haenszel method; RCT: Randomized control trial.

	MMA emboli		Conventional Mana			Risk Ratio		Risk Ratio		С
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 9	5% CI	<u> </u>
Observational Stu	idies Only									
Matsumoto et al, 2018	0	4	0	10		Not estimable				
Lam et al, 2023	0	0	0	0		Not estimable				
Ban et al, 2018	0	72	20	469	2.3%	0.16 [0.01, 2.57]	•		_	
Marulanda et al, 2021	1	25	1	25	2.4%	1.00 [0.07, 15.12]				
Onyinzo et al, 2021	1	50	10	82	4.3%	0.16 [0.02, 1.24]		•		
Kim et al, 2017	5	20	4	23	12.9%	1.44 [0.45, 4.63]				
Catapano et al, 2021	4	35	24	196	17.9%	0.93 [0.34, 2.53]			_	
Shotar et al, 2020	5	89	14	174	18.1%	0.70 [0.26, 1.88]				
Carpenter et al, 2021	7	23	63	185	42.0%	0.89 [0.47, 1.71]				
Subtotal (95% CI)		318		1164	100.0%	0.82 [0.54, 1.25]		-		
Total events	23		136							
Heterogeneity: Tau <sup>2</sup> = 0.	.00; Chi² = 5.38,	df = 6 (F	P = 0.50); I <sup>2</sup> = 0%							
Test for overall effect: Z	= 0.92 (P = 0.38	i)								
Total (95% CI)		318		1164	100.0%	0.82 [0.54, 1.25]		-		
Total events	23		136							
Heterogeneity: Tau <sup>2</sup> = 0.	.00; Chi <sup>2</sup> = 5.38,	df = 6 (F	P = 0.50); I <sup>2</sup> = 0%					0.1 1	10	100
Test for overall effect: Z:	= 0.92 (P = 0.36	i)					0.01 Eav	0.1 1 Durs MMA embolization Favo	10 ure Conventional Mana	
Test for subgroup different	ences: Not appl	icable					Fav	Nuis mma entrollization Favo	urs conventional Maria	gement



Risk ratio for safety endpoints (C), as reported in each trial, and mortality (D) for patients receiving adjunct MMA embolization to conventional management vs conventional management only. M-H indicates Mantel-Haenszel method.

# References


- 1. Feghali J, Yang W, Huang J. Updates in Chronic Subdural Hematoma: Epidemiology, Etiology, Pathogenesis, Treatment, and Outcome. *World Neurosurgery*. 2020;141:339-345. doi:10.1016/j.wneu.2020.06.140
- 2. Rauhala M, Helén P, Huhtala H, et al. Chronic subdural hematoma—incidence, complications, and financial impact. *Acta Neurochir*. 2020;162(9):2033-2043. doi:10.1007/s00701-020-04398-3
- 3. Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. *JNS*. 2015;123(5):1209-1215. doi:10.3171/2014.9.JNS141550
- 4. Ducruet AF, Grobelny BT, Zacharia BE, et al. The surgical management of chronic subdural hematoma. *Neurosurg Rev.* 2012;35(2):155-169. doi:10.1007/s10143-011-0349-y
- 5. Ironside N, Nguyen C, Do Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. *J NeuroIntervent Surg*. 2021;13(10):951-957. doi:10.1136/neurintsurg-2021-017352
- Davies J, Knopman J. Embolization of the Middle Meningeal Artery With ONYX<sup>™</sup> Liquid Embolic System for Subacute and Chronic Subdural Hematoma (EMBOLISE). ClinicalTrials.gov. Published June 24, 2024. https://clinicaltrials.gov/study/NCT04402632?tab=history&a=9#study-details-card
- Mao Y. Managing Non-acute Subdural Hematoma Using Liquid Materials : a Chinese Randomized Trial of MMA Treatment (MAGIC-MT). ClinicalTrials.gov. Published April 30, 2024. https://clinicaltrials.gov/study/NCT04700345
- 8. Fiorella D, Arthur A. The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) (STEM). ClinicalTrials.gov. Published August 16, 2023. https://clinicaltrials.gov/study/NCT04410146
- 9. Davies J, Knopman J. Embolise Study Interim Results from the Surgery Cohort. In: ; 2024. https://www.abstractsonline.com/pp8/#!/10942/presentation/3767
- Mao Y. Managing non-Acute SDH using liquid materials: a chinese randomized trial of MMA Treatment (MAGIC-MT). In: ; 2024. https://www.abstractsonline.com/pp8/#!/10942/presentation/3768
- 11. Fiorella D, Arthur A. Squid Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma Stem Trial. In: ; 2024. https://www.abstractsonline.com/pp8/#!/10942/presentation/3770
- 12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Journal of Clinical Epidemiology*. 2009;62(10):e1-e34. doi:10.1016/j.jclinepi.2009.06.006

- 13. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. Published online August 28, 2019:I4898. doi:10.1136/bmj.I4898
- 14. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions. *BMJ*. Published online October 12, 2016:i4919. doi:10.1136/bmj.i4919
- Rao G, Lopez-Jimenez F, Boyd J, et al. Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association. *Circulation*. 2017;136(10). doi:10.1161/CIR.00000000000523
- 16. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020. [n.d].
- 17. GRADEpro software. Accessed February 28, 2024. https://gdt.gradepro.org/app/#projects/p\_6a2cde5c-d39f-5fc9-8c87-1b9daae8942b\_5d34fc4a-0465-46ba-a73b-820cdd349f02/evidence-syntheses/9dea65ccbd3e-493d-9136-0057bbe093e1/quality-of-evidence
- Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. *Nat Rev Neurol*. 2014;10(10):570-578. doi:10.1038/nrneurol.2014.163
- Atefi N, Alcock S, Silvaggio JA, Shankar J. Clinical Outcome and Recurrence Risk of Chronic Subdural Hematoma After Surgical Drainage. *Cureus*. 2023;15(2):e35525. doi:10.7759/cureus.35525
- Désir LL, D'Amico R, Link T, et al. Middle Meningeal Artery Embolization and the Treatment of a Chronic Subdural Hematoma. *Cureus*. Published online October 18, 2021. doi:10.7759/cureus.18868
- Gerstl J, Shafi M, Badikol S, et al. E-049 Complications of middle meningeal artery embolization – a systematic review. In: SNIS 20th Annual Meeting Electronic Poster Abstracts. BMJ Publishing Group Ltd.; 2023:A105.1-A105. doi:10.1136/jnis-2023-SNIS.149
- 22. Sattari SA, Yang W, Shahbandi A, et al. Middle Meningeal Artery Embolization Versus Conventional Management for Patients With Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis. *Neurosurgery*. 2023;92(6):1142-1154. doi:10.1227/neu.00000000002365
- Lu H, Cole SR, Howe CJ, Westreich D. Toward a Clearer Definition of Selection Bias When Estimating Causal Effects. *Epidemiology*. 2022;33(5):699-706. doi:10.1097/EDE.00000000001516


# Supplemental Data:


Supplementary Figure 1: Risk of bias across and between studies.

Risk of bias summary for each individual study. Authors' judgments about each risk of bias item for each included study.



Aggregated risk of bias presented as percentages across all included studies.





Supplementary Figure 2: Risk of bias plots

Funnel plots for risk of bias by study type. Funnel plots obtained for all the studies included in the meta-analysis for hematoma recurrence (**panel A**), rates of reported good functional outcome (mRS <2) (**panel B**), risk of safety endpoints (**panel C**) and mortality risk (**panel D**).

# Supplemental Table 1. Hematoma Recurrence as defined in each study

Study	Hematoma Recurrence					
EMBOLISE, 2024	hematoma recurrence/progression requiring surgical drainage					
MAGIC-MT, 2024	hematoma maximum thickness exceeding 10 mm at 90 days or the patient receiving re-operation within 90 days in patients who underwent burr-hole drainage					
STEM, 2024	Residual or re-accumulation of the SDH (≥10 mm) on 180-day scan from intervention					
Onyinzo et al, 2021	CT findings in the follow-up period residual CSDH > 10mm					
Marulanda et al, 2021	Recurrence was defined as reaccumulating hematoma or continuous growth discovered on follow-up imaging with or without a new acute/subacute component					
Catapano et al, 2021	residual cSDH or reaccumulation > 10 mm					
Carpenter et al, 2021	re-accumulation of hematoma with symptoms requiring reoperation					
Shotar et al, 2020	reoperation to treat a recurrent CSDH previously treated by burr-hole craniostomy					
Ng et al, 2019	any radiologically persistent subdural collection with persistent or new symptoms attributable to CSDH					
Ban et al, 2018	incomplete hematoma resolution (remaining or reaccumulated hematoma with thickness > 10 mm					
Matsumoto et al, 2018	residual hematoma thickness of more than 50% or the absence of size reduction					
Kim et al, 2017	increase in the hematoma density and width					
Salih et al, 2023	SDH expansion after intervention or appearance of new acute components that warranted intervention or continuous close clinical and radiographic follow-up					
Lam et al, 2023	radiologically persistent or new cSDH with persistent or new symptoms secondary to the mass effect of the cSDH					

# Supplemental Table 2 . Safety End Points as defined in each study

Study	Safety End Points
EMBOLISE, 2024	Neurologic*, Brain abscessCerebellar/cerebral hemorrhage Cerebral infarctionDementiaEncephalopathyExtradural hematoma Gait disturbance Headache Neurological decompensation Neurological symptom Pneumocephalus Procedural complication Seizure/status epilepticusSOHSubduralWound infection Non-Neurologic*AnemiaAstheniaAtrial fibrillationCardiac arrestDysphagia Hepatic encephalopathyHypotensionMalnutritionNeuropathy (peripheral) PneumoniaRespiratory failure
MAGIC-MT, 2024	Symptomatic intracranial hemorrhage Surgery-related intracranial hemorrhage Surgery-related neurological deficits Surgery-related central nervous system infection Surgery-related arterial dissection, vascular wall injury and vascular reperforation Surgery-related ischemia Retroperitoneal/wrist hematoma Neuropathy at the puncture site Contrast allergy or contrast encephalopathy
STEM, 2024	Major disabling stroke, an increase in the NIHSS of 4 points or more from baseline that persists for 24 or more hours from the time of the event (major stroke), and results in a mRS of 3 or greater at 90 days from the event (disabling stroke)
Onyinzo et al, 2021	hematoma re-accumulation, acute re-bleeding, CSF fistula
Marulanda et al, 2021	Complications not defined/described after matching
Catapano et al, 2021	Overall Complications not defined
Carpenter et al, 2021	Seizure, pneumonia, urinary tract infections, acute kidney injury, stroke, DVT/PE, sepsis
Shotar et al, 2020	Epilepsy, empyema
Ng et al, 2019	surgical reoperation
Ban et al, 2018	Treatment related complication, Cerebral infarction
	Treatment related complication, acute epidural or subdural hematoma
	Treatment related complication, Surgical infection
	Treatment related complication, intracerebral hemorrhage
Matsumoto et al, 2018	surgical complications
Kim et al, 2017	surgical complications: intracranial bleeding, wound hematomas, post operative hemorrhage
	medical complications: seizure, angina pectoris, urinary tract infection, pneumonia and delirium
Salih et al, 2023	NR
Lam et al, 2023	Infection, new neurological deficits, seizures, pseudoaneurysms, retroperitoneal hemorrhage, allergic reactions to contrast or medications, stroke, intracerebral, hemorrhage, carotid dissection, deep vein thrombosis, pulmonary embolism, myocardial infarction

# Appendix 1

Embase

# **Search Algorithm**

.....

No. Query Results

#5. ((('subdural hematoma'/exp OR 'subdural

hematoma') AND middle AND meningeal AND artery AND embolization OR chronic) AND

subdural AND hemorrhage OR hematoma) AND recurrence AND embolization

#4. ((('subdural hematoma'/exp OR 'subdural hematoma') AND middle AND meningeal AND

artery AND embolization OR chronic) AND subdural AND hemorrhage OR hematoma) AND

recurrence AND embolization

#3. (('subdural hematoma'/exp OR 'subdural hematoma')

AND middle AND meningeal AND artery AND

embolization OR chronic) AND subdural AND

hemorrhage

#2. ((('subdural hematoma'/exp OR 'subdural hematoma') AND middle AND meningeal AND

artery AND embolization OR chronic) AND subdural AND hemorrhage OR hematoma) AND

recurrence

#1. 'subdural hematoma'/exp OR 'subdural hematoma'

.....

Results 601

601

1,653

9,574

24,688

Pubmed search algorithm

Search number Query Sort By Filters Search Details Results

4 (((((Middle Meningeal Artery Embolization) AND (chronic subdural hematoma)) AND (outcomes)) AND (surgery)) OR (burr hole) ) AND (recurrence) ((("middle"[All Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal" [All Fields] AND "arteries" [All Fields]) OR "meningeal arteries"[All Fields] OR ("meningeal"[All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]) AND ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations" [All Fields] OR "embolise" [All Fields] OR "embolised" [All Fields] OR "embolising" [All Fields] OR "embolism" [MeSH Terms] OR "embolism" [All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolizations" [All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields]) AND ("chronic subdural haematoma"[All Fields] OR "hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR ("chronic"[All Fields] AND "subdural"[All Fields] AND "hematoma"[All Fields])) AND ("outcome"[All Fields] OR "outcomes"[All Fields]) AND ("surgery"[MeSH Subheading] OR "surgery"[All Fields] OR "surgical procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] AND "procedures"[All Fields] AND "operative" [All Fields]) OR "operative surgical procedures" [All Fields] OR "general surgery" [MeSH Terms] OR ("general" [All Fields] AND "surgery" [All Fields]) OR "general surgery" [All Fields] OR "surgery s" [All Fields] OR "surgerys"[All Fields] OR "surgeries"[All Fields])) OR ("trephining"[MeSH Terms] OR "trephining"[All Fields] OR ("burr"[All Fields] AND "hole"[All Fields]) OR "burr hole"[All Fields])) AND ("recurrance" [All Fields] OR "recurrence" [MeSH Terms] OR "recurrence" [All Fields] OR

"recurrences" [All Fields] OR "recurrencies" [All Fields] OR "recurrency" [All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields]) 710 3 ((((Middle Meningeal Artery Embolization) AND (chronic subdural hematoma)) AND (outcomes)) AND (surgery)) OR (burr hole) (("middle"[All Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields] OR ("meningeal"[All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]) AND ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised"[All Fields] OR "embolising"[All Fields] OR "embolism"[MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization" [All Fields] AND "therapeutic" [All Fields]) OR "therapeutic embolization" [All Fields] OR "embolisation" [All Fields] OR "embolization" [All Fields] OR "embolizations" [All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes" [All Fields] OR "embolizing"[All Fields]) AND ("chronic subdural haematoma"[All Fields] OR "hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR ("chronic"[All Fields] AND "subdural"[All Fields] AND "hematoma"[All Fields])) AND ("outcome"[All Fields] OR "outcomes"[All Fields]) AND ("surgery"[MeSH Subheading] OR "surgery"[All Fields] OR "surgical procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] AND "procedures"[All Fields] AND "operative" [All Fields]) OR "operative surgical procedures" [All Fields] OR "general surgery"[MeSH Terms] OR ("general"[All Fields] AND "surgery"[All Fields]) OR "general surgery"[All Fields] OR "surgery s"[All Fields] OR "surgerys"[All Fields] OR "surgeries"[All Fields])) OR ("trephining"[MeSH Terms] OR "trephining"[All Fields] OR ("burr"[All Fields] AND "hole"[All Fields]) OR "burr hole"[All Fields]) 3,978

2 (hematoma, subdural, chronic (MeSH)' OR 'chronic" OR 'subdural hematoma' AND 'meningeal arteries (MeSH)' OR 'middle meningeal artery' AND 'embolization, therapeutic'

(MeSH) OR 'embolization' AND 'recurrence') OR (embolization and recurrence)
(((((((("hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND
"subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR
"hematoma subdural chronic"[All Fields]) AND ("medical subject headings"[MeSH Terms] OR
("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject
headings"[All Fields] OR "mesh"[All Fields])) OR ("chronic"[All Fields] OR "chronical"[All Fields]
OR "chronically"[All Fields] OR "chronicities"[All Fields] OR "chronicity"[All Fields] OR
"chronicization"[All Fields] OR "chronics"[All Fields]) OR ("subdural haematoma"[All Fields] OR
"hematoma, subdural"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields]))
OR "subdural hematoma"[All Fields] OR ("subdural"[All Fields] AND "hematoma"[All Fields]))
OR "subdural hematoma"[All Fields] OR ("subdural"[All Fields] AND "hematoma"[All Fields])))
AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "hematoma"[All Fields]))
OR "meningeal arteries"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR
("medical"[All Fields] AND "subject"[All Fields] AND "hematoma"[All Fields]]))
OR "meningeal arteries"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR
("medical"[All Fields] AND "subject"[All Fields]]) OR (("middle"[All Fields])) OR "medical subject
headings"[All Fields] OR "mesh"[All Fields]])) OR (("middle"[All
Fields] OR "medical subject
[All Fields] OR "mesh"[All Fields]])) OR (("middle"[All
Fields] OR "medical subject
[All Fields] OR "mesh"[All Fields]])) OR (("middle"[All
Fields] OR "medical subject

Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields] OR ("meningeal"[All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]))) AND ("embolization,

therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolization therapeutic"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised"[All Fields] OR "embolising"[All Fields] OR "embolism"[MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisations"[All Fields] OR "embolization, OR "embolizations"[All Fields] OR "embolize"[All Fields] OR "embolized"[All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields])) AND ("recurrance"[All Fields] OR "recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrencies"[All Fields] OR "recurrency"[All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields])) OR (("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised"[All Fields] OR "embolising"[All Fields] OR "recurrents"[All Fields])) OR (("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised"[All Fields] OR "embolicing"[All Fields] OR "embolism"[MeSH Terms] OR "embolism"[All Fields] OR "embolization"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolize"[All Fields] OR "embolized"[All Fields] OR "embolizes"[All Fields] OR "embolize"[All Fields] OR "embolized"[All Fields] OR "embolizes"[All Fields] OR "embolize"[All Fields] OR "embolized"[All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields] OR "embolized"[All Fields] OR "recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrences"[All Fields] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrences"[All Fields] OR "recurrences"[All Fields] OR "recurrent"[All Fields] OR "recurrences"[All Fields] OR "recurrences"[All Fields] OR "recurrents"[All Fields] OR "recurrences"[All Fields] OR "recurrences"[All Fields] OR "recurrents"[All Fields] OR "recurrences"[All Fields] OR "recurrences"[All Fields] OR "recurrents"[All Fields] OR "recurrents"[All Fields])) 19,903

1 (hematoma, subdural, chronic (MeSH)' OR 'chronic' OR 'subdural hematoma' AND 'meningeal arteries (MeSH)' OR 'middle meningeal artery' AND 'embolization, therapeutic' (MeSH) OR 'embolization' AND 'recurrence' ) OR (conventional management) (((((((("hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR "hematoma subdural chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR "hematoma subdural chronic"[All Fields]) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields]] OR "mesh"[All Fields]] OR ("chronic"[All Fields] OR "chronical"[All Fields]] OR "chronicities"[All Fields]] OR "chronicities"[All Fields]] OR "chronicities"[All Fields]] OR "chronicities][All Fields]] OR "chronical"[All Fields]] OR "chronicities"[All Fields]] OR "chronicities][All Fields]] OR "chroniciti

Fields] OR ("subdural"[All Fields] AND "hematoma"[All Fields]))) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR (("middle"[All

Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries" [All Fields]) OR "meningeal arteries" [All Fields] OR ("meningeal" [All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]))) AND ("embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolization therapeutic"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR ("embol" [All Fields] OR "embolics" [All Fields] OR "embolisations" [All Fields] OR "embolise" [All Fields] OR "embolised" [All Fields] OR "embolising" [All Fields] OR "embolism" [MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolizations" [All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields])) AND ("recurrance"[All Fields] OR "recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrencies"[All Fields] OR "recurrency"[All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields])) OR (("conventional"[All Fields] OR "conventionals"[All Fields]) AND ("manage"[All Fields] OR "managed"[All Fields] OR "management s"[All Fields] OR "managements"[All Fields] OR "manager"[All Fields] OR "manager s"[All Fields] OR "managers"[All Fields] OR "manages"[All Fields] OR "managing"[All Fields] OR "managment" [All Fields] OR "organization and administration" [MeSH Terms] OR

("organization" [All Fields] AND "administration" [All Fields]) OR "organization and administration"[All Fields] OR "management"[All Fields] OR "disease management"[MeSH Terms] OR ("disease"[All Fields] AND "management"[All Fields]) OR "disease management"[All Fields])) 91,460 ClinicalTrials.gov NCT Number Interventions NCT04410146 for Treatment of Chronic Subdural Hematoma (STEM) https://clinicaltrials.gov/study/NCT04410146 ACTIVE NOT RECRUITING Subdural Hematoma, Chronic DEVICE: SQUID Embolization DEVICE: SQUID Embolization and Surgical Evacuation PROCEDURE: Surgical Evacuation OTHER: Other: Medical Management Balt USA **INTERVENTIONAL** Study Title Study URL Study Status Conditions Sponsor Collaborators Study Type The SQUID Trial for the Embolization of the Middle Meningeal Artery NCT03307395 Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT03307395 COMPLETED Chronic Subdural Hematoma PROCEDURE: Middel Meningeal Artery Embolization Weill Medical College of Cornell University INTERVENTIONAL NCT04500795 Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma https://clinicaltrials.gov/study/NCT04500795 WITHDRAWN Chronic Subdural Hematoma|Subdural Hematoma PROCEDURE: Middle meningeal artery embolization Chinese University of Hong Kong INTERVENTIONAL NCT04270955 Dartmouth Middle Meningeal Embolization Trial (DaMMET)

https://clinicaltrials.gov/study/NCT04270955 COMPLETED Chronic Subdural Hematoma|Subdural Hematoma PROCEDURE: Embolization of the Middle Meningeal Artery|PROCEDURE: Standard of care including possible surgical evacuation of subdural hematoma Dartmouth-Hitchcock Medical Center

# INTERVENTIONAL

NCT04511572 Embolization of Middle Meningeal Artery in Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT04511572 RECRUITING Chronic Subdural Hematomas PROCEDURE: embolization of the middle meningeal artery Academisch Medisch Centrum -Universiteit van Amsterdam (AMC-UvA) INTERVENTIONAL NCT04574843 Middle Meningeal Artery Embolization With Liquid Embolic Agent for Treatment of Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT04574843 RECRUITING Chronic Subdural Hematoma PROCEDURE: Embolization of MMA Mashhad University of Medical Sciences

# INTERVENTIONAL

NCT05374681 Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization https://clinicaltrials.gov/study/NCT05374681 RECRUITING Chronic Subdural Hematoma OTHER: Medical treatment|OTHER: Surgical treatment|OTHER: embolization of the MMA University Hospital, Brest

# INTERVENTIONAL

NCT04742920 The Onyxâ,,¢ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma (OTEMACS) https://clinicaltrials.gov/study/NCT04742920 RECRUITING Hematoma, Subdural, Chronic|Brain Diseases|Central Nervous System Diseases|Wounds and Injuries

DEVICE: Middle Meningeal Artery Embolization|PROCEDURE: Standard Management University Hospital, Montpellier INTERVENTIONAL

NCT04095819 Middle Meningeal Artery (MMA) Embolization Compared to Traditional Surgical Strategies to Treat Chronic Subdural Hematomas (cSDH)

https://clinicaltrials.gov/study/NCT04095819 UNKNOWN Chronic Subdural Hematoma PROCEDURE: Middle Meningeal Artery procedure|PROCEDURE: Traditional Surgery Atlantic Health System INTERVENTIONAL

NCT06274580 Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms https://clinicaltrials.gov/study/NCT06274580

NOT\_YET\_RECRUITING Subdural Hematoma, Chronic DEVICE: embolization of the middle meningeal artery Ospedale Policlinico San Martino

INTERVENTIONAL

alone Unfallkrankenhaus Berlin

NCT04816591 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA https://clinicaltrials.gov/study/NCT04816591 RECRUITING Chronic Subdural Hematoma DEVICE: Experimental: Interventional Cohort: Treatment Arm|OTHER: Active Comparator: Interventional Cohort: Control Arm|DEVICE: Experimental: Observational Cohort: Treatment Arm|OTHER: Active Comparator: Observational Cohort: Control Arm Cerenovus, Part of DePuy Synthes Products, Inc. INTERVENTIONAL NCT04065113 Middle Meningeal Artery Embolization for Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT04065113 RECRUITING Chronic Subdural Hematoma PROCEDURE: Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|PROCEDURE: Drainage of Subdural Hematoma Washington University School of Medicine INTERVENTIONAL

NCT05327933 Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization https://clinicaltrials.gov/study/NCT05327933 RECRUITING Hematoma, Subdural, Chronic PROCEDURE: Surgery plus endovascular MMA embolization|PROCEDURE: Surgery

**INTERVENTIONAL** 

NCT06163547 Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM) https://clinicaltrials.gov/study/NCT06163547 NOT YET RECRUITING

Chronic Subdural Hematomas|Cerebral Compression Due to Injury RADIATION: MMA embolization University Hospital, Geneva INTERVENTIONAL NCT04372147 Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT) https://clinicaltrials.gov/study/NCT04372147 UNKNOWN Chronic Subdural Hematoma|at Risk of Post-operative Recurrence|Burr-hole Surgery PROCEDURE: MMA embolization Assistance Publique - Hôpitaux de Paris INTERVENTIONAL